Long Island Man Sebastien Beauzile Becomes First New Yorker Cured of Sickle Cell Disease With Lyfgenia Gene Therapy

Sebastien Beauzile spent most of his childhood measuring time in hospital beds. The 21-year-old from Laurelton, Queens, who grew up on Long Island, lived with sickle cell disease so severe that pain crises could lock his joints and send him back through the same emergency-room doors week after week. On December 17, 2024, doctors at Cohen Children’s Medical Center infused him with Lyfgenia, a one-time gene therapy that rewrites how his bone marrow makes hemoglobin. By March 13, 2025, his hematologist was willing to say the words patients with this disease almost never hear: the sickle cell disease is gone.

« I’m not in pain anymore, » Beauzile told reporters at the press conference Northwell Health staged to mark what he calls his « re-birthday. » Staff sang « Happy Birthday. » He answered with a line that now follows him around the internet: « I’m unstoppable. »

The AEGIS Alliance is following his case because it is not only a medical first for New York. It is a test of whether a $3.1 million therapy can leave the press conference and reach the 100,000 people in the United States who still live with the same mutation.

What sickle cell does to a body

Sickle cell disease is a genetic error in hemoglobin, the protein that lets red blood cells carry oxygen. Instead of sliding through vessels as flexible discs, the cells collapse into rigid crescents. Those crescents jam small arteries. The result is vaso-occlusive pain, stroke risk, organ damage, and a shortened life. In the United States the condition hits Black families hardest. About 1 in 365 Black or African American babies is born with it.

For decades the toolkit stopped at pain medicine, transfusions, and hydroxyurea. A matched bone-marrow transplant could cure a lucky few. Most patients never found a donor. Beauzile’s life followed the common script. « I was basically in and out of the hospital, » he said. « I believe I spent more time in the hospital than I did at home. » During a crisis, movement itself became the enemy. « You can’t walk. You can’t move. You can’t do anything. »

How Lyfgenia actually works

Lyfgenia, sold as lovotibeglogene autotemcel by bluebird bio, does not edit the broken gene the way CRISPR does. Technicians harvest the patient’s own hematopoietic stem cells, then use a disabled lentivirus to insert a working copy of a hemoglobin gene. That insert tells the cells to manufacture HbAT87Q, a hemoglobin designed to resist sickling. The patient then receives busulfan chemotherapy to empty the bone marrow. The modified cells go back in through an intravenous line and, if the graft takes, start producing blood that no longer collapses.

The U.S. Food and Drug Administration approved Lyfgenia in December 2023 for patients 12 and older with a history of vaso-occlusive events. The same month it approved Casgevy, the CRISPR-based rival from Vertex and CRISPR Therapeutics. Lyfgenia carries a boxed warning. Two people treated with an earlier version of the platform later developed acute myeloid leukemia. Recipients are told to stay in lifelong cancer surveillance.

Cohen Children’s became the first hospital in New York State to administer the commercial product. Dr. Banu Aygun, Beauzile’s hematologist, told local outlets the rewrite of his marrow had held. CBS New York reported that he has been free of crises since the December infusion.

The price of a one-time cure

A list price of about $3.1 million is not a rounding error for a Medicaid program. Casgevy lists near $2.2 million. Both therapies demand specialized centers, weeks of isolation, and fertility counseling because busulfan can sterilize a patient. Those barriers showed up in the sales reports. Roughly two years after approval, only a few dozen people with sickle cell disease had received an infusion of either product. Bluebird was taken private after struggling to sell its gene therapies. Vertex reported modest early Casgevy revenue and a pipeline of patients whose cells had been collected but not yet infused.

Federal officials tried to pry the door open. The Centers for Medicare and Medicaid Services launched a Cell and Gene Therapy Access Model that ties payment to outcomes and lets states buy the drugs through a coordinated deal. By mid-2025, 33 states plus the District of Columbia and Puerto Rico had signed on, covering about 84 percent of Medicaid beneficiaries with sickle cell disease. New York is also pouring capital into the manufacturing side. Governor Kathy Hochul and Northwell Health announced a cell and gene therapy campus in Lake Success, now branded New York Biogenesis Park, with a first-phase tower planned on Northwell’s campus and state money of up to $150 million behind a larger buildout targeted for the end of the decade.

A first in New York, not a first on Earth

Beauzile is New York’s first commercial Lyfgenia success, not the first person ever treated this way. In January 2024, 12-year-old Kendric Cromer of the Washington suburbs became the first person in the world to start a commercially approved sickle cell gene therapy after the FDA green light. Victoria Gray, treated in a CRISPR trial in 2019, had already shown that editing fetal hemoglobin genes could shut the disease down. An 8-year-old in New York separately became the state’s first patient to receive an FDA-approved gene therapy for beta-thalassemia, a cousin blood disorder. The science is no longer theoretical. The bottleneck is capacity, money, and the willingness of hospitals to stand up the apheresis and transplant infrastructure.

New York Blood Center staff who ran Beauzile’s three collection sessions have described the work as a quiet piece of the milestone. Advocacy groups have tried to keep the disease visible. NewYork-Presbyterian’s Dalio Center for Health Justice launched an #IBall4SickleCell campaign around a special-edition basketball, a reminder that a condition this common in Black communities still fights for attention and research dollars.

What unstoppable actually means

Beauzile’s new life is built out of ordinary sentences. He can hike. He can swim. He can stand in cold air without assuming the weather will put him back in a ward. « I don’t have to worry about getting sick from the cold, » he said. « I’ve been going outside in the cold, and I’ve been fine. » Travel, once a calculation about whether a crisis would hit far from his doctors, is now on the table.

That human scale is the point The AEGIS Alliance keeps coming back to. A gene therapy that works in one Long Island infusion room is a story. A system that can repeat it for tens of thousands of people is a policy fight. Similar medical leaps, from a titanium heart that walked an Australian patient out of hospital to a fungal molecule synthesized after 50 years for childhood brain tumors, run into the same wall: proof in a single body does not automatically become access.

The unfinished part of the story

Doctors will watch Beauzile for malignancy for the rest of his life. Insurers will watch the invoice. States in the CMS model will watch whether the outcomes they paid for actually appear. Other New Yorkers with sickle cell disease are already in workups at the same Northwell program. Some will be offered Casgevy instead. Some will be told their organs are too damaged, or that they cannot tolerate the chemotherapy step.

For one 21-year-old, the argument is already over. The blockade he described is behind him. Whether the rest of the country gets the same chance depends on factories in Lake Success, Medicaid contracts in 33 statehouses, and a health system that has historically underfunded the people this mutation hits first. Beauzile’s re-birthday is real. The waiting list behind him is real too.